Log in to search using one of your social media accounts:

 

Villafa ña-founded artificial vessel developer Medical 21 looks to raise $15m

St. Jude Medical founder Manny Villafaña’s newest medtech play, Medical 21, is looking to raise $15 million in an equity round of funding, according to an SEC filing posted recently. The company is developing an artificial blood vessel as an alternative to harvesting blood vessels for coronary artery bypass surgeries, and has already begun animal testing of the technology, according to a Twin Cities Business report. Bypass surgeries, which are performed over 500,000 times a year in the US, require surgeons to harvest blood vessels from a patient’s body to be stitched into the heart to repair the circulatory system. The development of an artificial vessel could significantly change how the procedures are performed, according to the report – a goal that Medical 21 hopes to see to fruition. “People have tried for 40 or 50 years to do this and no one has done it. We figure we can save $10,000 to $20,000 per patient, not to mention the pain and rehabilitation. It’s a pursuit that has to be done. We keep tearing up people’s arms and legs and costing their healthcare system enormous dollars. So I’m going after the holy grail,” Villafaña told TCB. Medical 21 is using a new material developed by the University of Iowa and licensed to the company to make its artificial vessels, something Villafaña says gives him confidence, according to the report. The material consists of cellulose graft conduits supported by a thin ...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Cardiovascular medical21 Source Type: news

Related Links:

ConclusionTadalafil shares a similar efficacy and safety with sildenafil and significantly improves patients ’ sexual confidence. Furthermore, patients and their partners prefer tadalafil to sildenafil. Hence, tadalafil may be a better choice for ED treatment.
Source: International Urology and Nephrology - Category: Urology & Nephrology Source Type: research
Federal regulators have approved Medtronic ’s latest device for treating chronic pain: A small implant that’s rechargeable and interfaces with a Samsung tablet computer. The medical-device giant’s Intellis system features a device that, according to Medtronic, is the world’s smallest spinal-cord stimulator. The device is roughly 2.2 inches tall and 1.9 inches wide. Like other spinal-cord stimulators, the product works by emitting electrical pulses that stop pain signals. Physicians can use…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news
The FDA has approve the   Intellis spinal cord stimulation platform   for the management of chronic intractable pain of the trunk and/or limbs associated with a variety of conditions.FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Psychiatry News Alert Source Type: news
Medtronic won FDA approval and is releasing in the U.S. its Intellis spinal cord neurostimulation platform, which includes the world’s smallest fully implantable spinal cord neurostimulator. The system delivers both high-dose and low-dose therapy, depending on the patient’s needs, and tracks patient activity to help physicians improve how the therapy targets individual’s pain. It is made to wirelessly, and securely, interface with a Samsung Galaxy Tab S2 tablet which is used by the physician to adjust settings and set parameters that best address the patient’s needs. The same tablet can be used...
Source: Medgadget - Category: Medical Devices Authors: Tags: Neurology Neurosurgery Pain Management Source Type: blogs
Medtronic (NYSE:MDT) said today it won FDA approval for its Intellis implantable spinal cord stimulation system and launched it in the US. The Fridley, Minn.-based company touted the newly revised system as the world’s smallest, and said that the new unit was designed to improve battery performance and standardize guidance and balancing of high-dose and low-dose therapy settings. “Drawing upon our 40-year legacy in SCS, the launch of the Intellis platform isn’t just about a new device, but about combining cutting edge hardware with optimal therapy through the Evolve workflow to enable personalized, l...
Source: Mass Device - Category: Medical Devices Authors: Tags: Food & Drug Administration (FDA) Neuromodulation/Neurostimulation Regulatory/Compliance Spinal Medtronic Source Type: news
The European leg of her “ Joanne ” tour, scheduled to start Thursday in Barcelona, will be pushed back to 2018. She had canceled a show in Brazil last week.
Source: NYT Health - Category: Consumer Health News Authors: Tags: Pop and Rock Music Lady Gaga Fibromyalgia Joanne (Album) Europe Gaga: Five Foot Two (Movie) Source Type: news
This article originally appeared on PEOPLE.com.
Source: TIME.com: Top Science and Health Stories - Category: Consumer Health News Authors: Tags: Uncategorized awards emmys emmys 2017 onetime Source Type: news
ConclusionBased on the Grand Round case and relevant literature, we present a case of a highly aggressive and fast-growing tumor with a very high local and distant recurrence. There is no consensus treatment plan available and patients usually die shortly after diagnosis.
Source: European Spine Journal - Category: Orthopaedics Source Type: research
ConclusionsClinicians ’ beliefs about the risk for acute LDH associated with chiropractic SMT varied systematically across professions, in spite of a lack of scientific evidence to inform these beliefs. These probability distributions can serve as prior probabilities in future Bayesian analyses of this relationship.
Source: European Spine Journal - Category: Orthopaedics Source Type: research
Last week I discussed some of the areas in the brain, and basic principles, that are currently thought to influence our pain experience. This week I thought I’d introduce one of my favourite ways of considering pain mechanisms, mainly because it helps me think through the four main kinds of mechanisms, and can influence our treatment approach. At this stage I want to raise my hand to acknowledge the following: My gratitude to Dr John Alchin, longtime friend and colleague, who first pointed this paper out to me and has shared it with hundreds of people who go to see him at the local tertiary pain management centre. W...
Source: HealthSkills Weblog - Category: Anesthesiology Authors: Tags: Education Pain Pain conditions Research Science in practice biopsychosocial Chronic pain Health pain management Source Type: blogs
More News: Back Pain | Cardiology | Cardiovascular | Cardiovascular & Thoracic Surgery | Coronary Artery Bypass Graft | Funding | Gastroschisis Repair | Heart | Heart Transplant | Men | Pain | Rehabilitation